3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Status
Recruiting
3
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Observational
1
Sponsor
Cancer Type
Thoracic
7
Other hematologic neoplasm
5
CNS
5
Tumor-Agnostic
4
Sarcoma
4
Other solid neoplasm
4
Lymphoid
4
Head & Neck
4
Genitourinary
4
Gastrointestinal
4
Dermatologic
4
Breast
4
Endocrine
3
Gynecologic
2
Plasma cell
1
NET
1
Myeloid
1
Classical hematology
1
Conditions
Neoplasms
2
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
94
Paclitaxel
85
Gemcitabine
83
Carboplatin
79
Docetaxel
60
Cisplatin
58
Bevacizumab
58
Nivolumab
56
Fluorouracil
47
Capecitabine
46
Magnetic Resonance Spectroscopy
44
Radiotherapy
41
Irinotecan
40
Oxaliplatin
38
Erlotinib Hydrochloride
37
Pemetrexed
34
Leucovorin
34
Biopsy
34
atezolizumab
33
Cetuximab
32
Standard of Care
31
Trastuzumab
28
Cyclophosphamide
28
Radiosurgery
27
Blood Specimen Collection
27
Specimen Handling
26
Sorafenib
26
Ipilimumab
26
Everolimus
26
olaparib
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Interventional
×
entrectinib
×
Tumor-Agnostic
×
Clear all
NCT05862285
2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3
Recruiting
100 enrolled
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts
NCT04817956
2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2
Recruiting
3,000 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled